Form 4 for EXEL EXELIXIS, INC.
Accepted 2021-07-28 00:00:00 ET · period of report 2021-07-26 · accession 0000939767-21-000074 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-07-28 | 2021-07-26 | EXEL | Schwab Gisela | Pres, CMO, Prod Dev, Med Aff | M - OptEx | $4.20 | +40.0K | 689.1K | +6% | +$168.0K |
| D | 2021-07-28 | 2021-07-26 | EXEL | Schwab Gisela | Pres, CMO, Prod Dev, Med Aff | M - OptEx | $0.00 | -40.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-07-26 | M | A | 40,000 | $4.20 | 689,078 | D | — | — | (F1) Includes 243,968 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. |
| 2 | Derivative | Option (right to buy) | 2021-07-26 | M | D | 40,000 | $0.00 | 0 | D | $4.20 · 2017-02-11 to 2023-02-10 | 40,000 Common Stock | (F3) The option, representing the right to purchase a total of 75,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 11, 2020. |